Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AssigneeChemoCentryx, Inc.
InventorsJennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
Life of this patent
Estimating the term…
Abstract
Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
Claims38
A method of identifying an agent that binds to CCX-CKR2 on a cell, the method comprising,
- contacting a plurality of agents to a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2, or a SDF1 or I-TAC-binding fragment thereof;
- and
- selecting an agent that competes with I-TAC or SDF1 for binding to the CCX-CKR2 polypeptide or fragment thereof, thereby identifying an agent that binds to CCX-CKR2 on a cell.
A method for determining the presence or absence of a cancer cell, the method comprising,
- contacting a sample comprising a cell with an agent that specifically binds with SEQ ID NO:2;
- and
- detecting binding of the agent to a polypeptide in the sample, wherein binding of the agent to the sample indicates the presence of a cancer cell.
A method of providing a diagnosis or prognosis of an individual having cancer, the method comprising detecting the presence or absence of expression of a polynucleotide encoding a CCX-CKR2 polypeptide in a cell of an individual, wherein the CCX-CKR2 polypeptide binds I-TAC and/or SDF1 and the CCX-CKR2 polypeptide is at least 95% identical to SEQ ID NO:2, thereby diagnosing a cancer in the individual.
An antibody that specifically competes with SDF-1 and I-TAC for binding to SEQ ID NO:2.
A method comprising,
- contacting a cell with an agent that specifically binds to SEQ ID NO:2, wherein the agent competes with SDF-1 and I-TAC for binding to a CCX-CKR2 polypeptide, and wherein the cell expresses a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2, thereby binding the agent to the CCX-CKR2 polypeptide on the cell.
A method of treating cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an agent that competes with SDF1 and I-TAC for binding to SEQ ID NO:2.
Dependencies are inferred from the claim text.